
-
Quartararo sets Spanish MotoGP record to claim pole
-
Hamas says open to 5-year Gaza truce, one-time hostages release
-
Iran, US hold new round of high-stakes nuclear talks
-
Up at dawn for front-row seat to history at Francis's funeral
-
Pakistan ready to 'defend sovereignty' after India threats
-
Huge crowds flock to Vatican for Pope Francis's funeral
-
Xi says China must 'overcome' AI chip challenges
-
Indian army says new exchange of gunfire with Pakistan
-
Epstein accuser Virginia Giuffre takes own life in Australia: family
-
Hundreds of buildings damaged, dozens injured in 6.3 Ecuador quake
-
India and Pakistan's Kashmir fallout hits economy too
-
Francis's funeral to be grand farewell to 'pope of the poor'
-
Pogacar faces defiant Evenepoel at Liege-Bastogne-Liege
-
Chelsea eye great escape against Barcelona in Women's Champions League
-
Iran, US to hold new round of high-level nuclear talks
-
'Energy and effort' pay off for Reds as Blues' woes continue
-
Albatross and closing birdie lift China's Liu to LPGA Chevron lead
-
On the horizon? Wave of momentum for high seas treaty
-
Top Mistakes to Avoid When Building Credit History
-
Developing countries should fast-track US trade deals: World Bank president
-
Grizzlies' Morant 'doubtful' for must-win game 4 v Thunder
-
Trump in Rome for pope funeral in first foreign trip of new term
-
Trump says Russia-Ukraine deal 'very close' after new Kremlin talks
-
US rookies lead PGA pairs event with McIlroy and Lowry in hunt
-
Trump tariff promises get a reality check
-
Warriors coach Kerr 'relatively optimistic' injured Butler will play game 3
-
Postecoglou hopes 'Stonecutter's Credo' can inspire Spurs
-
PSG lose unbeaten Ligue 1 record ahead of Arsenal showdown
-
Venezuela accuses El Salvador president of 'human trafficking'
-
Own goal takes Sundowns to African final against Pyramids
-
Scores of buildings damaged, 20 injured in Ecuador quake
-
US stocks extend rally as market eyes busy calendar next week
-
Pope's death triggers surge of disinformation he fought against
-
Rovanpera takes control of Rally Islas Canarias
-
Zelensky insists Crimea is Ukrainian as US envoy meets Putin
-
Patel and Mendis help Sunrisers beat Kings in Dhoni's 400th T20
-
Copa del Rey ref statements 'unacceptable': Real Madrid after boycotting final build-up
-
Insurance CEO's accused killer pleads not guilty to federal murder charges
-
FBI arrests Wisconsin judge for shielding undocumented migrant
-
Brazil ex-president Collor de Mello jailed for corruption
-
Zelensky insists Crimea 'belongs' to Ukraine as US envoy meets Putin
-
Real Madrid boycott Copa del Rey build-up over referee complaints
-
Trinidad and Tobago votes for parliament, PM, with opposition in lead
-
IMF chief hails 'constructive' Spring Meetings held under tariff uncertainty
-
Iran FM Araghchi in Oman ahead of nuclear talks with US
-
Dozens of buildings destroyed, 20 injured in Ecuador quake
-
Young Barca must 'enjoy' Real Madrid Copa final fight: Flick
-
Pakistan and India border closure separates families
-
Brazil's Bolsonaro 'stable' after post-surgery setback
-
Catholics in secular Cuba hail Francis as 'bridge'

Patients regain much weight after stopping new obesity drug: study
A new generation of obesity drugs often delivers dramatic weight loss, but many patients wonder what happens when they stop treatment.
One study published Monday in the Journal of the American Medical Association provides an answer: much of the weight comes back, signaling patients may be locked into long term dependence on the drugs.
The research was based on weekly injections of tirzepatide, the compound in Eli Lilly's new weight loss drug Zepbound that was approved by the United States last month.
After 36 weeks, 670 adults achieved a notable mean weight loss of 20.9 percent.
The group was then split into two, with half continuing on Zepbound, and the other half given a placebo.
At 88 weeks, those on the placebo regained almost half of the weight they had lost, ending up 9.9 percent lower than their baseline.
Those on Zepbound continued to lose weight, ending 25.3 percent lower than where they had started.
The trial patients were mostly women and had a mean age of 48, with a mean weight at the outset was 107.3 kilograms (236.6 pounds).
All participants were encouraged to consume 500 calories less each day than they burnt and take at least 150 minutes of exercise per week.
Common side effects were gastrointestinal issues including nausea, diarrhea, constipation and vomiting, said the study.
- Growing evidence -
Study authors, led by Louis Aronne at Weill Cornell Medicine, New York, said the results "emphasize the need to continue pharmacotherapy to prevent weight regain and ensure the maintenance of weight reduction."
They added the latest research adds to four previous trials that showed "medications, including potent antiobesity medications such as semaglutide, have demonstrated that weight is substantially regained" after stopping treatment.
Semaglutide is the active ingredient in Novo Nordisk's Ozempic and Wegovy, which, like Zepbound, are examples of so-called "GLP-1 agonists" that work by mimicking the function of a hormone that secretes insulin, slows down the emptying of the stomach, and suppresses appetite.
Zepbound also contains another molecule that acts like the gut hormone GIP.
In response to the study, Lilly's Jeff Emmick said in a statement that "patients, providers and the public do not always understand obesity is a chronic disease that often requires ongoing treatment, which can mean that treatment is stopped once weight goals are met."
GLP-1 agonists have been found to cut the risk of cardiovascular disease associated with obesity -- but they also heighten the risk of gastrointestinal problems, studies show.
Though the rates of serious issues such as stomach paralysis are low, some experts fear that using the drugs for years or decades could change the benefit-to-risk calculus.
Cost can also be a disincentive. Zepbound costs $1,059.87 per month, and insurance companies often do not cover weight loss medications. Medicare, state subsidized insurance for the elderly, is barred from covering it.
D.Sawyer--AMWN